Latest Aemetis Inc (AMTX) Headlines Aemetis Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Aemetis Inc (AMTX) Headlines

Aemetis Announces Commissioning of Biodiesel Distillation Unit at India Plant
Business Wire - Tue Feb 04, 7:45AM CST
Aemetis, Inc. (OTCQB: AMTX), an advanced fuels and renewable chemicals company, announced today that its 50 million gallon per year capacity biodiesel and refined glycerin production facility in Kakinada, India has been upgraded to produce high-quality distilled biodiesel. The Aemetis plant was built in 2008 using advanced technology to produce biodiesel and refined glycerin using large volumes of lower-cost, non-food by-products from the edible oil industry as feedstock to supply the biofuel, pharmaceutical, and industrial markets.

Aemetis Announces EPA Approval as the First Converted Corn Ethanol Plant to Produce D5 Advanced Biofuels Using Sorghum/Biogas/CHP
Business Wire - Tue Sep 03, 7:45AM CDT
Aemetis, Inc. (OTCQB: AMTX), an advanced fuels and renewable chemicals company, announced today that the US Environmental Protection Agency (EPA) has granted Aemetis approval to produce ethanol using grain sorghum and biogas with the plant's existing Combined Heat & Power (CHP) system to generate higher-value D5 Advanced Biofuels Renewable Identification Numbers (RINs).

Aemetis Announces Restart of 60 Million Gallon Per Year Keyes Biofuels Plant
Business Wire - Mon Apr 22, 7:45AM CDT
Aemetis, Inc. (OTCQB: AMTX), an advanced fuels and renewable chemicals company, announced today that the Aemetis 60 million gallon per year capacity ethanol facility in Keyes, California has completed planned maintenance and preparations for the production of Advanced Biofuel under recent EPA rulings, and is now restarting production.

Chromatin Signs Multi-Year Agreement with Aemetis to Supply Locally-Grown Sorghum for Ethanol Production
Business Wire - Wed Feb 20, 8:00AM CST
Chromatin, Inc., a leading provider of innovative crop breeding technology, sorghum seed products and feedstocks, and Aemetis, Inc. (OTCPK: AMTX), an advanced fuels and renewable chemicals company announced today that they have entered into a multi-year agreement to source locally-grown grain sorghum. Under the agreement, Chromatin will engage local growers to plant its hybrid grain sorghum on up to 30,000 acres, and Aemetis will use that sorghum in its Keyes, CA, facility to produce Advanced Biofuels.

Aemetis Announces Shareholder Conference Call at 1:15 PM PT on December 20, 2012
Business Wire - Tue Dec 18, 6:29PM CST
Aemetis, Inc. (OTCPK: AMTX), an advanced fuels and renewable chemical company, announced today that the company will host a business update conference call at 1:15 PM, Pacific Daylight Time on December 20, 2012.

Aemetis, Inc. (AMTX) Stock Research Links

AMTX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading